“The 0/1 hr algorithm using the ADVIA Centaur High-Sensitivity Troponin I Assay is very safe and effective in triaging patients with suspected NSTEMI.”
Acute coronary syndrome (ACS) is typically suspected based on clinical symptoms and ECGs. However, if the ECG change is not significant, an acute myocardial infarction may be difficult to diagnose. At Japan’s largest hospital, Professor Junichi Ishii and his team investigated the Siemens Healthineers High-Sensitivity Troponin I Assay to see the role it plays in diagnosing ACS when combined with clinical symptoms, physical findings, and ECGs.
Professor Ishii presented his study, “Prospective Validation of the 0/1h Triage Algorithm Using High-Sensitivity Cardiac Troponin I for Acute Myocardial Infarction,” at the 2020 European Society of Cardiology Congress, during which new non-ST-segment-elevation acute coronary syndrome guidelines were introduced. Professor Ishii’s results confirmed that the ADVIA Centaur® High-Sensitivity Troponin I Assay met the latest ESC guidelines and aligned with the Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) algorithm validation published in 2018.
A recent article in the European Medical Journal highlighted Professor Ishii’s study.
Professor Ishii presents two case findings from his study, showing how early intervention based on hs-cTnI results allowed them to find small myocardial damage that had not been detected by an ECG.